explore -WSS

explore

author：focus 2025-09-30 12:08:15 - browse：571

Sammy Kimball for STAT

Is Wegovy really a brain drug? Which Alzheimer’s disease treatment works best? And what’s the point of Threads?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Megan Molteni joins us to explain the evolving science suggesting products like Wegovy are less weight loss drugs than treatments for human desire. We also explain why this summer is shaping up to be a pivotal moment for the treatment of Alzheimer’s and discuss our befuddlement with the latest social media platform.

For more on what we cover, here’s the story on GLP-1 drugs and the brain; here’s the latest on Leqembi; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Pfizer plans to depart BIO

WSS

The woman behind the Dana Farber

Pfizer plans to depart BIO

Radiology is caught between AI's potential and concern for patients

STAT letters to the editor on burnt

Americans' trust in science, scientist continues decline: Report

Radiology is caught between AI's potential and concern for patients

focus

explore

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

SCOTUS to consider access to abortion pill mifepristone

DIEP, the 'gold standard' of breast reconstruction, is under threat

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Apple is now the first public company to be valued at $3 trillion

Why sickle cell disease is getting the first CRISPR treatment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

SCOTUS to consider access to abortion pill mifepristone

United colonoscopy coverage change 'may cost lives,' doctors say

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

focus

What PEPFAR has meant on the ground in Ukraine

Can medical device makers keep up in the race to treat obesity?

A public health expert passes on football's full body collisions for youths

Pfizer plans to depart BIO

What PEPFAR has meant on the ground in Ukraine

CMS should re

knowledge

explore

focus

focus